Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Immersion Investment Partners. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD+39.1%
YTD+10.4%
Positioning StanceConstructive
Market CapSMID Cap
Digest Analysis
Quick Take
"The concentrated micro- and small-cap fund added capital near Q1 lows in companies like Red Violet and Mama's Creations, where temporary factors created gaps between price and value."
Executive Summary
Immersion Investment Partners returned 39.1% in Q2 2026, significantly outperforming the Russell 2000's 21.5% gain, as the market began pricing non-AI holdings more rationally after an irrational Q1 selloff. The fund operates a concentrated micro- and small-cap portfolio, adding the S&P SmallCap 600 as a benchmark because it better represents their investable universe of profitable, liquid companies. The managers view selloffs driven by macroeconomic noise as opportunities to add to positions at attractive prices, which they did near the Q1 lows. Key holdings include Red Violet, whose AI-driven identity platform is benefiting from AI trends rather than being threatened by them, and Mama's Creations, which was sold off on a timing mismatch between Q1 expenses and Q2 revenue from new Walmart product launches. The fund initiated a position in Strata Critical Medical, a leading organ transplant logistics provider positioned to consolidate a fragmented industry while benefiting from regulatory changes and new technologies expanding the donor pool. The managers emphasize that their process remains identical through market volatility, re-underwriting each holding to ensure fundamentals remain intact.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
82%
CautiousHigh
High Conviction (82%)
The fund operates a highly concentrated portfolio with five largest holdings explicitly named and discussed in detail. The managers provide specific position sizing language for Strata Critical Medical, stating they expect to earn five to eight times their investment. They describe re-underwriting each holding during volatility and adding capital where the gap between price and value appeared widest. The letter includes detailed, multi-paragraph thesis explanations for Red Violet, Mama's Creations, and Strata Critical Medical with specific financial metrics and catalysts. The managers state 'we know what we believe each position is worth and why' and demonstrate willingness to add through volatility. This is high conviction with clear, falsifiable theses and concentrated positioning.
Growth Outlook
40%
BearishBullish
Neutral (40%)
The managers acknowledge that markets are not always rational and describe Q2 as a reversal of Q1's irrational selloff. They state that 'in a rational market, the underlying business progress that supported it would continue to be recognized. But we all know that markets are not always rational.' This reflects a mildly positive but cautious view, recognizing that the Q2 recovery was driven by sentiment normalization rather than fundamental change. The tone is constructive but acknowledges ongoing volatility.
Risk Appetite
55%
DefensiveAggressive
Balanced (55%)
The fund added capital near the Q1 lows where the gap between price and value appeared widest, demonstrating a willingness to deploy capital into volatility. However, this was selective deployment based on re-underwriting each holding rather than aggressive across-the-board risk-taking. The managers describe maintaining their concentrated portfolio through the selloff and adding selectively, which indicates a net long, risk-on tilt but with discipline. The positioning is bullish but measured.
Capital Deployment
45%
De-riskingDeploying
Net Neutral (45%)
The fund added capital near the Q1 lows where the gap between price and value appeared widest, indicating moderate deployment activity. However, no specific cash level changes are provided, and the letter describes this as selective deployment rather than aggressive across-the-board capital deployment. The managers also initiated a new position in Strata Critical Medical in September 2025. The activity suggests moderate deployment with a selective approach, scoring in the moderate deployment range but below aggressive deployment given the lack of specific cash reduction data.
Forward Guidance
30%
CautiousExpansionary
Cautious (30%)
The managers provide no explicit guidance on future deployment plans. They state that 'the only thing we can promise is that our process on the way down will look identical to our process on the way up' and that they will 'continue to evaluate both the macroeconomic environment and what is happening within each company.' This is monitoring language with no clear directional action bias. The tone is one of preserving optionality and waiting for opportunities rather than actively deploying or de-risking.
Language Signal
50%
BearishBullish
Balanced (50%)
The letter contains balanced directional language. Bullish language includes 'attractive opportunity set,' 'expected return has increased,' 'revenue continued compounding,' 'earnings converted into cash flow,' and 'compelling growth.' Bearish or cautious language includes 'markets are not always rational,' 'lumpy fashion,' 'macroeconomic noise,' and 'volatility.' The overall balance leans slightly positive, with more emphasis on opportunities created by volatility than on risks, but the tone is measured rather than overwhelmingly bullish.
Perceived Risk
45%
Low RiskElevated
Moderate Risk (45%)
The managers acknowledge that markets are not always rational and that concentrated micro- and small-cap portfolios should expect lumpy returns. They identify macroeconomic noise as a source of volatility and note that AI-related sentiment can drive irrational pricing. However, these risks are framed as creating opportunities rather than as systemic threats. The discussion is moderate in depth, with risks mentioned but not central to the letter's narrative. The tone is cautious but not alarmed, placing this in the moderate risk acknowledgment range.
Opportunity Density
70%
ScarceAbundant
Abundant (70%)
The managers describe an 'attractive opportunity set' being presented to them during the Q1 selloff and state that 'when the noise is loudest, the opportunity is often greatest.' They initiated a new position in Strata Critical Medical and added to existing holdings. The letter discusses multiple compelling opportunities across Red Violet, Mama's Creations, and Strata Critical Medical with detailed theses. This indicates a selective but rich opportunity set, with the managers finding multiple attractive ideas in their defined micro- and small-cap universe.
Time Horizon
75%
Short-TermLong-Term
Decade+ (75%)
The managers describe a multi-year investment horizon with emphasis on businesses where 'revenue continues compounding, earnings convert into cash flow, and management teams continue doing the small, unglamorous things that tend to appear in the financial statements many quarters later.' For Strata Critical Medical, they project EBITDA growth over the next five years and state they expect to earn five to eight times their investment. The fund structure and language suggest a 2-5 year thesis with willingness to hold through short-term volatility. This is a multi-year horizon with no near-term catalyst dependency, placing it in the 0.65-0.84 range.